HOME
LINK
SITE MAP
Japanese Page
about kissei
research & development
investor relations
Investor Relations
Annual Report
News Release
2010
2009
2008
2007
2006
Financial Summary
R&D Pipeline
News Release
●July 2, 2010
Preliminary Results of Phase III clinical study of KUC-7483
●May 26, 2010
Announcement for Launching "Epoetin Alfa BS Injection [JCR]", a Treatment Agent for Renal Anemia
●April 30, 2010
License Agreement of “Genetically Engineered Proaerolysin” for the Treatment of Benign Prostatic Hyperplasia
●February 4, 2010
European Commission Approved SILODOSIN (Brand Name in Japan: Urief®) for The Treatment of Dysuria Associated with Benign Prostatic Hyperplasia
